Clinical trials: Treatment naïve
Hepatitis C Infection
Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks
The aim of the study is to evaluate in clinical practice the efficacy and safety of ombitasvir/paritaprevir/ ritonavir and dasabuvir administered for 8 weeks in treatment-naïve participants with genotype 1b hepatitis C virus…
- Trial name
- 3D8 (NCT03122132)
- Testing
- ombitasvir/paritaprevir/ritonavir 8 weeks, dasabuvir 8 weeks
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Hepa C
Paroxysmal Nocturnal Hemoglobinuria (PNH)
ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
The primary purpose of this study was to assess the noninferiority of ravulizumab compared to eculizumab in adult participants with PNH who had never been treated with a complement inhibitor (treatment-naïve).
- Trial name
- NCT02946463
- Testing
- Ravulizumab, Eculizumab
- Where
- 120 sites in United States, Argentina and 24 more
- Volunteers
- 272 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Type 2 Diabetes (T2D)
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
This study is an open-label, 1:1 randomized, active-controlled, 2-arm, 20-week treatment duration, parallel-group, multicenter, phase IV study to evaluate the effect of iGlarLixi versus Gla-100 on glycemic control measured as TIR…
- Trial name
- China Soli-CGM (NCT06671587)
- Testing
- iGlarLixi (insulin glargine/lixisenatide), Gla-100 (insulin glargine)
- Where
- China
- Volunteers
- 678 people
- Sponsor
- Sanofi
Acute Myeloid Leukemia (AML)
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
The primary objective of this study is to evaluate if venetoclax when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia…
- Trial name
- NCT03069352
- Testing
- Venetoclax, Cytarabine
- Where
- 109 sites in United States, Argentina and 22 more
- Volunteers
- 211 people
- Sponsor
- AbbVie
Wet Age-related Macular Degeneration
Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease
In this observational study researchers want to learn more about changes in visual acuity (clarity of vision) with proactive flexible treatments over time in patients suffering from wet age-related macular degeneration (wAMD)…
- Trial name
- XTEND (NCT03939767)
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- 17 sites in Argentina, Australia and 15 more
- Volunteers
- 1,563 people
- Sponsor
- Bayer
Lung Cancer
Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC
This is a prospective, multicenter, randomized, open label study to investigate the efficacy and safety of osimertinib plus bevacizumab versus osimertinib montherapy in treatment-naïve recurrent or metastatic NSCLC patients…
- Trial name
- NCT04988607
- Testing
- Osimertinib, Bevacizumab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Guangdong Association of Clinical Trials
Fabry Disease
A Study of Replagal in Treatment-naïve Adults With Fabry Disease
In this study, adults with Fabry Disease who have not had any treatment for this condition will be treated with Replagal. The main aim of the study is to check if Replagal improves kidney function and heart structure of…
- Trial name
- NCT04840667
- Testing
- REPLAGAL
- Where
- 28 sites in Canada, Finland and 6 more
- Volunteers
- 17 people
- Sponsor
- Shire
Crohn Disease
Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year
The purpose of this study is to compare the efficacy of treatment with ustekinumab or adalimumab in biologic naive participants with moderately-to-severely active Crohn's disease (CD) who have previously failed or were intolerant…
- Trial name
- SEAVUE (NCT03464136)
- Testing
- Ustekinumab (6 mg/kg), Ustekinumab (90 mg), Adalimumab (40 mg)
- Where
- 182 sites in United States, Australia and 16 more
- Volunteers
- 386 people
- Sponsor
- Janssen Scientific Affairs, LLC
Acute Myeloid Leukemia
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well Venetoclax works to treat AML in adult participants who are ineligible for…
- Trial name
- VALOR (NCT05215639)
- Where
- 19 sites in Austria, Switzerland
- Volunteers
- 120 people
- Sponsor
- AbbVie
HIV Infections
Nutritional Status Among naïve HIV Infected Patients and HIV Infected Patients Receiving Highly Active Antiretroviral Therapy
A prospective cross-sectional study evaluates nutritional status and its relationship to the related factors in Thai HIV-infected patients who attending in out patient clinic.
- Trial name
- TNT-HIV 001 (NCT01899157)
- Where
- Thailand
- Volunteers
- 580 people
- Sponsor
- Thai Red Cross AIDS Research Centre
HIV Infection
Repeated DermaVir Immunizations in HIV-1 Infected Treatment-naïve Patients
DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a single plasmid DNA expressing fifteen HIV antigens that assemble to HIV-like particles.
- Trial name
- GIEU006 (NCT00711230)
- Testing
- DermaVir
- Where
- 3 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Genetic Immunity
Opioid Analgesic Treatment Response, Chronic Pain
Predictive Markers of the Effects of Opioid Therapy
The overall goal of the ABILITY study is to help improve pain diagnostics and treatment by developing an implementable clinical computerised decision support system based on individual patient characteristics.
- Trial name
- ABILITY (NCT02308306)
- Where
- 5 sites in Belgium, Denmark and 1 more
- Volunteers
- 62 people
- Sponsor
- University of Aarhus
Advanced Prostate Cancer
Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
The purpose of this study is to detect factors influencing decision making for treatment pathways of hormone-naïve prostate cancer patients with and without comorbidities receiving medicinal androgen deprivation therapy…
- Trial name
- ProComD (NCT02234089)
- Testing
- Degarelix, LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)
- Where
- Germany
- Volunteers
- 461 people
- Sponsor
- Ferring Pharmaceuticals
Melanoma Metastatic
Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma Study
The association between microbiota and response to ICI-based therapy reflects the ability of bacterial metabolites to upregulate MHC class I APM component expression and/or function in cancer cells, leading to their elimination…
- Trial name
- NCT07050940
- Testing
- Postbiotic, AntiPD1
- Where
- 5 sites in Italy
- Volunteers
- 35 people
- Sponsor
- Azienda Ospedaliera di Perugia
Moderate to Severe Pain Due to Diabetic Polyneuropathy
A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy
To show superior analgesic efficacy of OXN PR in addition to a patient's current dose of pregabalin compared to pregabalin alone.
- Trial name
- NCT00944697
- Testing
- Oxycodone Naloxone
- Where
- Germany
- Volunteers
- 98 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Diabetes, Diabetes Mellitus, Type 2
Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment
This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood glucose lowering effect and the safety profile of repaglinide given alone compared to gliclazide given alone in Chinese subjects with…
- Trial name
- NCT01022762
- Testing
- repaglinide, gliclazide
- Where
- China
- Volunteers
- 440 people
- Sponsor
- Novo Nordisk A/S
Hepatitis C, Chronic
Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection
This study examined the influence of ribavirin on the initial virological response in treatment-naïve participants with chronic hepatitis C, genotype 1.
- Trial name
- NCT02716779
- Testing
- Pegylated Interferon (PEG-IFN) alfa-2a, Ribavirin
- Where
- 5 sites in Germany
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer
This study will evaluate the efficacy, safety, and pharmacoeconomics of oral capecitabine in patients with metastatic colorectal cancer.
- Trial name
- NCT02567331
- Testing
- Capecitabine
- Where
- 5 sites in Bulgaria
- Volunteers
- 28 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic, Hepatitis C
Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209)
The objective of the study is to evaluate the rates of Hepatitis C virus (HCV) eradication and relapse in participants treated with PegIntron and Rebetol in clinical practice in Greece.
- Trial name
- NCT00724464
- Testing
- PegIntron (peginterferon alfa-2b, pegylated interferon alfa-2b), Rebetol (ribavirin)
- Volunteers
- 332 people
- Sponsor
- Merck Sharp & Dohme LLC
Myelodysplastic Syndromes
A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States
The purpose of this study is to understand real-world effectiveness of luspatercept treatment among erythropoiesis-stimulating agents -naïve patients with lower-risk- myelodysplastic syndromes in the United States
- Trial name
- NCT06851065
- Testing
- Luspatercept, Erythropoiesis-stimulating agents
- Where
- United States
- Volunteers
- 418 people
- Sponsor
- Bristol-Myers Squibb